TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24428754
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg daily for 7 days
Study: 24428754
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily for 7 days
Study: 19887304
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 40 mg/m² on day 1, continuous infusion ifosfamide (IFO) 1700 mg/m² on days 1-3, mesna, every 28 days for 6-9 cycles
Study: 17823365
Drug: Statin/ACEI combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin/ACEI combination treatment at standard doses (STD, ramipril 2.5/simvastatin 20 mg, or atorvastatin 10 mg)
Study: 17823365
Drug: Statin/ACEI combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin/ACEI combination treatment at high doses (HiDo, ramipril 10 mg, or enalapril 20 mg/simvastatin 80 mg, or atorvastatin 40 mg)
Study: 17823365
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses (HiDo) treatment
Study: 17823365
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses (STD) treatment
Study: 11057354
Drug: Patanol (olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patanol (olopatadine hydrochloride ophthalmic solution 0.1%) with placebo tablet
Study: 11057354
Drug: Claritin (loratadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Claritin (loratadine 10 mg) with placebo
Study: 8363164
Drug: Psyllium, 5.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium, 5.1 g twice a day
Study: 29993221
Drug: Bio-modulator patch
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-modulator patch
Study: 26822397
Drug: Gastrectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastrectomy followed by chemotherapy
Study: 23875987
Drug: WTQ-G advertisements
Approvals — FDA: no, EMA: no, PMDA: no
Description: WTQ-G advertisements (graphic images)
Study: 23875987
Drug: WTQ-T +
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WTQ-T + HTQ advertisements (combination)
Study: 15108107
Drug: Submucosal epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Submucosal epinephrine injection (1/10,000)
Study: 11666122
Drug: Oral TTFCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TTFCA (60 mg tablets twice daily) for 4 weeks
Study: 8013765
Drug: Propafenone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (900 mg/daily)
Study: 8013765
Drug: Flecainide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (300 mg/daily)
Study: 3057851
Drug: Diltiazem (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (260 mg/day)
Study: 3057851
Drug: Hydrochlorothiazide (52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (52 mg/day)
Study: 23370314
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and carboplatin with conatumumab (3 mg/kg)
Study: 23370314
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and carboplatin with conatumumab (15 mg/kg)
Study: 23370314
Drug: Conatumumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conatumumab treatment among V-allele carriers
Study: 23370314
Drug: Conatumumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conatumumab treatment among F-allele homozygotes
Study: 17601495
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 6 mg
Study: 17466492
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 9 mg
Study: 17601495
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 12 mg
Study: 17092691
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (all doses)
Study: 11152164
Drug: Complementary/alternative medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary/alternative medicine (CAM) therapies
Study: 9186298
Drug: Oral ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ingestion of 100 g glucose (OGTT)
Study: 9186298
Drug: 100-g protein
Normalized name: soy protein isolate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-g protein meal
Study: 8247951
Drug: Ketanserin 60
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 60 mg daily for 3 weeks
Study: 8247951
Drug: Ketanserin 120
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 120 mg daily for 3 weeks
Study: 3530444
Drug: Doxorubicin (ADR)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (ADR) 75 mg/m2 by iv bolus every 3 weeks
Study: 3530444
Drug: Doxorubicin (ADR)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (ADR) 45 mg/m2 by iv bolus every 3 weeks and Mitomycin (MMC) 10 mg/m2 by iv bolus every 6 weeks
Study: 24612915
Drug: 2 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml/kg 30% lipid emulsions
Study: 20697169
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline (250 μg) followed by oral terbutaline (20 mg/d) as maintenance
Study: 20697169
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (0.1 mg) followed by oral salbutamol (24 mg/d) as maintenance
Study: 1810356
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release metoclopramide 15 mg (Gastrobid Continus tablets) given twice daily
Study: 1810356
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg given three times daily
Study: 1810356
Drug: Domperidone 20
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 20 mg given three times daily
Study: 1810356
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release metoclopramide and domperidone (both doses)
Study: 6636262
Drug: Heparinized plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized plasma at 4.0 ng/ml
Study: 6636262
Drug: Serum at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum at 4.0 ng/ml
Study: 6636262
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation procedures
Study: 28510741
Drug: Early FFP
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early FFP administration (FFP in the CPB priming solution)
Study: 28510741
Drug: Late FFP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late FFP administration (FFP given immediately after CPB)
Study: 20337077
Drug: One-visit endodontic
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit endodontic treatment
Study: 21185738
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mixed tocopherols 666 IU/day and alpha lipoic acid (ALA) 600 mg/day for 8 weeks
Study: 18803070
Drug: Ziprasidone 80‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 80‐160 mg/day (n=147)
Study: 18803070
Drug: Olanzapine 10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10‐20 mg/day (n=24)
Study: 18803070
Drug: Risperidone 4‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4‐8 mg/day (n=22)
Study: 18803070
Drug: Quetiapine 300‐750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 300‐750 mg/day (n=97)
Study: 9825977
Drug: Erythromycin 40
Normalized name: erythromycin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 40 mg/kg/d, intravenously or orally
Study: 2668325
Drug: sc injections
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc injections of SMS 201‐995 every 2 hours (q2h)
Study: 2668325
Drug: sc injections
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc injections of SMS 201‐995 every 8 hours (q8h)
Study: 1245160
Drug: Clofibate preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate preparation 1
Study: 1245160
Drug: Clofibate preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate preparation 2
Study: 31525257
Drug: Xylocaine spray
Normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylocaine spray (8 puffs of 10% Lidocaine, 80 mg)
Study: 31525257
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no spray)
Study: 26799692
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg once daily + Sofosbuvir 400 mg once daily for 12 weeks
Study: 26799692
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg once daily + Sofosbuvir 400 mg once daily for 8 weeks
Study: 24117232
Drug: Adjunctive moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive moderate dose lithium therapy
Study: 24117232
Drug: Optimized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized treatment
Study: 22530944
Drug: eGFR 30.0-59.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR 30.0-59.9 mL/min/1.73 m²
Study: 22530944
Drug: eGFR ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR ≥ 90.0 mL/min/1.73 m²
Study: 16926184
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with sulfasalazine and methotrexate (MTX)
Study: 12760727
Drug: Intrasphincteric injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasphincteric injections of botulinum toxin (group 1: 10 patients)
Study: 12760727
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of 1% polidocanol (group 2: 6 patients)
Study: 12760727
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with botulinum toxin and polidocanol (group 3: 6 patients)
Study: 9357940
Drug: HIV-infected patients
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-infected patients responding to antiretroviral therapy
Study: 8453557
Drug: Regional RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional RT plus six cycles of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Study: 8453557
Drug: Regional RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional RT plus six cycles of CHOP chemotherapy
Study: 3769386
Drug: Sotalol 160
Normalized name: sotalol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 160 mg/day
Study: 3769386
Drug: Sotalol 240
Normalized name: sotalol 240 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 240 mg/day
Study: 3769386
Drug: Sotalol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (all doses)
Study: 26543645
Drug: Dexmedetomidine, 1 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine, 1 µg/kg (group D)
Study: 26543645
Drug: Midazolam, 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, 0.02 mg/kg (group M)
Study: 22080997
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS (20 Hz, 10 second trains, intensity 80% of motor threshold) for 10 minutes daily for five consecutive days
Study: 11456360
Drug: Valaciclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 1000 mg three times daily for 7 days
Study: 9623637
Drug: L-T4 replacement
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-T4 replacement treatment in hypothyroid patients
Study: 25264024
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (4 mg/kg median)
Study: 23553259
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 4% lidocaine (anesthetized condition)
Study: 19755925
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 (P500)
Study: 19755925
Drug: Pemetrexed 1000
Normalized name: pemetrexed 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 1000 mg/m2 (P1000)
Study: 17092968
Drug: TPA023 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA023 0.5 mg
Study: 17092968
Drug: TPA023 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA023 1.5 mg
Study: 11261347
Drug: Soft hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft hydrogel contact lenses worn daily for 12 months
Study: 2543280
Drug: Intranasal alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal alpha 2b interferon (IFN) 5 x 10(6) IU on day 1 and 2.5 x 10(6) IU on each subsequent day for 5 days
Study: 23485660
Drug: Multimodal manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal manual treatment approach (joint mobilization, neural mobilization, and exercise)
Study: 23485660
Drug: Multimodal manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal manual treatment approach
Study: 17205144
Drug: Valsartan (Diovan)
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan (Diovan) 80 mg/day for 7 days
Study: 15132875
Drug: Mosapride 5
Normalized name: mosapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 5 mg three times daily for 4 weeks
Study: 15132875
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg three times daily for 4 weeks
Study: 11402745
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for two weeks
Study: 11402745
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for ten days
Study: 9143861
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg to 50 mg daily after 6 weeks)
Study: 1826192
Drug: ANF infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANF infusion at 1 pmol/kg/min
Study: 1826192
Drug: ANF infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANF infusion at 3 pmol/kg/min
Study: 1826192
Drug: ANF infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANF infusion at 10 pmol/kg/min
Study: 25867537
Drug: Second-line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line chemotherapy
Study: 26367239
Drug: Third-line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-line chemotherapy
Study: 26084590
Drug: Etanercept continuous
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept continuous regimen (50 mg/week)
Study: 17080277
Drug: Perianal local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perianal local anesthesia (40 ml of ropivacaine, 4.75 mg/ml, plus 15 ml of ropivacaine, 2 mg/ml)
Study: 14971717
Drug: Flavonoid extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid extract (Colladeen, 320 mg oligomeric procyanidins)
Study: 10186469
Drug: Ribosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribosomal vaccine (Ribomunyl)
Study: 2968060
Drug: Loratadine 80
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine 80 mg
Study: 18310201
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no emollient therapy)
Study: 12823564
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs (AEDs) in monotherapy
Study: 31822251
Drug: Thrombolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis treatment
Study: 8396000
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment until relapse
Study: 3714767
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 2 mg/70 kg
Study: 3714767
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 4 mg/70 kg
Study: 24610413
Drug: Royal jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal jelly supplementation (1,000 mg daily for 8 weeks)
Study: 10761763
Drug: Fludarabine (Flu)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (Flu) 25 mg/m2 for five consecutive days every four weeks
Study: 10761763
Drug: Cladribine (CdA)
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine (CdA) 0.14 mg/kg for five consecutive days every four weeks
Study: 10761763
Drug: Cross-over treatment
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-over treatment after failure
Study: 1407981
Drug: Topical medication
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medication and/or laser trabeculoplasty
Study: 6726903
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (1,600 rad for 4 days)
Study: 6726903
Drug: Contemporary surgery
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contemporary surgery without preoperative radiation therapy
Study: 30509743
Drug: 100 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg/kg oral morphine sulphate
Study: 24856057
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (20 international units)
Study: 23768677
Drug: STOP IT
Normalized name: DIPHENHYDRAMINE HYDROCHLORIDE 2 g in 100 mL TOPICAL GEL [Walgreens Stop Itch Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: STOP IT program (integrated treatment for PTSD and smoking)
Study: 20805642
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intravenous methylprednisolone)
Study: 15928250
Drug: DHEA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (100 mg/d)
Study: 15928250
Drug: APZ (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: APZ (0.5 mg)
Study: 15928250
Drug: DHEA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA and APZ in combination
Study: 12181240
Drug: 5-FU plus
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU plus cisplatin (FUP) - continuous 5-FU 1000 mg/m2/day for 5 days plus cisplatin 100 mg/m2 on day 1 or day 2
Study: 12181240
Drug: 5-FU (FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU (FU) - 5-FU 500 mg/m2/day for 5 days
Study: 10600332
Drug: ALLERVAX CAT
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLERVAX CAT (750 microg/dose)
Study: 8635183
Drug: L-deprenyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-deprenyl (10 mg daily) as an adjunct to low-dose bromocriptine (up to 25 mg daily)
Study: 8635183
Drug: L-deprenyl plus
Normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-deprenyl plus bromocriptine
Study: 2126361
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 micrograms in a single oral dose)
Study: 2126361
Drug: Insulin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.15 IU/kg BW in an i.v. bolus)
Study: 832432
Drug: NaCl supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl supplements of 200 mEq/day
Study: 832432
Drug: Daily mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mixture of NaHCO3 (100 mEq) and NaCl (100 mEq)
Study: 30723316
Drug: Citalopram (dose-dependent)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (dose-dependent)
Study: 30723316
Drug: Citalopram (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (high dose)
Study: 30723316
Drug: Citalopram (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (low dose)
Study: 28723597
Drug: Intra tympanic
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra tympanic Gentamicin (40 mgs/ml)
Study: 28723597
Drug: Intra tympanic
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra tympanic Dexamethasone (0.5 ml, 4 mgs/ml)
Study: 28723597
Drug: Intra tympanic
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra tympanic Normal Saline (0.5 ml)
Study: 22193396
Drug: Retrograde intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrograde intravenous delivery of 100 million bone marrow mononuclear cells (BMMC) through the IVC route
Study: 11040903
Drug: Oral fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluorescein angiography (OFA)